Multiple Sclerosis Journal - October 2017 - 1504

Multiple Sclerosis Journal 23(11)
Sanofi-Aventis. C.E. has received funding for travel
and speaker honoraria from Biogen Idec, Bayer
Schering Pharma, Merck Serono, Novartis Genzyme
and Teva Pharmaceutical Industries Ltd./SanofiAventis; research support from Merck Serono, Biogen
Idec. and Teva Pharmaceutical Industries Ltd./SanofiAventis; serving on scientific advisory boards for
Bayer Schering Pharma, Biogen Idec, Genzyme,
Merck Serono, Novartis and Teva Pharmaceutical
Industries Ltd./Sanofi-Aventis; academic editor for
PLoS One. F.F. serves on scientific advisory boards
for Biogen Idec, Genzyme, Merck Serono, Novartis,
Roche and Teva Pharmaceutical Industries Ltd.;
serves on the editorial boards of Multiple Sclerosis,
the Polish Journal of Neurology and Neurosurgery
and the Swiss Archives of Neurology and Psychiatry;
provides services for Actelion and Parexel and has
received speaker honoraria and support from Almirall,
Merck Serono, Novartis, Pfizer, Roche, Shire and
Teva Pharmaceutical Industries Ltd. M.K. has
received funding for travel and speaker honoraria
from Bayer Schering Pharma, Novartis Genzyme,
Merck Serono, Biogen Idec and Teva Pharmaceutical
Industries.
Funding
The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This study represents a sub-study
supported by the Austrian Federal Ministry of Science,
Research and Economics (core-study named 'BIGWIG MS' (Bildgebung, Immunpathogenese,
Gesundungsfaktoren - Wien, Innsbruck, Graz - bei
Multiple Sklerose'; 'Neuroimaging, immunopathogenesis and salutogenic factors in MS - a collaborative effort of the universities of Vienna, Innsbruck and
Graz')). This study was further supported by an unrestricted research grant from TEVA Pharmaceutical
Industries Ltd.

References
1. Polman CH, Reingold SC, Banwell B, et al.
Diagnostic criteria for multiple sclerosis: 2010
Revisions to the McDonald criteria. Ann Neurol 2011;
69(2): 292-302.
2. Hassan-Smith G, Durant L, Tsentemeidou A,
et al. High sensitivity and specificity of elevated
cerebrospinal fluid kappa free light chains in
suspected multiple sclerosis. J Neuroimmunol 2014;
276(1-2): 175-179.
3. Presslauer S, Milosavljevic D, Huebl W, et al. Kappa
free light chains: Diagnostic and prognostic relevance
in MS and CIS. PLoS ONE 2014; 9(2): e89945.

1504

4. Duranti F, Pieri M, Centonze D, et al. Determination
of κFLC and κ index in cerebrospinal fluid: A valid
alternative to assess intrathecal immunoglobulin
synthesis. J Neuroimmunol 2013; 263(1-2): 116-120.
5. Presslauer S, Milosavljevic D, Huebl W, et al.
Validation of kappa free light chains as a diagnostic
biomarker in multiple sclerosis and clinically isolated
syndrome: A multicenter study. Mult Scler 2015;
22(4): 502-510.
6. Kaplan B, Aizenbud BM, Golderman S, et al. Free
light chain monomers in the diagnosis of multiple
sclerosis. J Neuroimmunol 2010; 229(1-2): 263-271.
7. Senel M, Tumani H, Lauda F, et al. Cerebrospinal
fluid immunoglobulin kappa light chain in clinically
isolated syndrome and multiple sclerosis. PLoS ONE
2014; 9(4): e88680.
8. Arneth B and Birklein F. High sensitivity of free
lambda and free kappa light chains for detection of
intrathecal immunoglobulin synthesis in cerebrospinal
fluid. Acta Neurol Scand 2009; 119(13): 39-44.
9. Kuhle J, Distanto G, Dobson R, et al. Conversion
from clinically isolated syndrome to multiple
sclerosis: A large multicentre study. Mult Scler 2015;
21(8): 1013-1024.
10. Tintoré M, Rovira A, Río J, et al. Do oligoclonal
bands add information to MRI in first attacks of
multiple sclerosis? Neurology 2008; 70(13 Pt 2):
1079-1083.
11. Villar LM, Espiño M, Costa-Frossard L, et al. High
levels of cerebrospinal fluid free kappa chains predict
conversion to multiple sclerosis. Clin Chim Acta
2012; 413(23): 1813-1816.
12. Desplat-Jégo S, Feuillet L, Pelletier J, et al.
Quantification of immunoglobulin free light chains in
cerebrospinal fluid by nephelometry. J Clin Immunol
2005; 25(4): 338-345.
13. Makshakov G, Nazarov V, Kochetova O, et al.
Diagnostic and prognostic value of the cerebrospinal
fluid concentration of immunoglobulin free light
chains in clinically isolated syndrome with conversion
to multiple sclerosis. PLoS ONE 2015; 10(11): 1-12.
14. Mcdonald WI, Compston A, Edan G, et al.
Recommended diagnostic criteria for multiple
sclerosis: Guidelines from the International Panel on
the diagnosis of multiple sclerosis. Ann Neurol 2001;
50: 121-127.
15. Teunissen C, Menge T, Altintas A, et al. Consensus
definitions and application guidelines for control groups
in cerebrospinal fluid biomarker studies in multiple
sclerosis. Mult Scler 2013; 19(13): 1802-1809.
16. Kurtzke JF. Rating neurologic impairment in multiple
sclerosis: An expanded disability status scale (EDSS).
Neurology 1983; 33: 1444-1453.

journals.sagepub.com/home/msj

https://journals.sagepub.com/home/msj

Table of Contents for the Digital Edition of Multiple Sclerosis Journal - October 2017